Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target
Morgan Stanley has maintained its 'Hold' rating on Recursion Pharmaceuticals (RXRX) while adjusting its price target to $5.60.
Stocks · News reference
Recursion Pharmaceuticals reported its financial results for the third quarter ended September 30, 2026, alongside updates on its clinical pipeline and platform execution.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Morgan Stanley has maintained its 'Hold' rating on Recursion Pharmaceuticals (RXRX) while adjusting its price target to $5.60.
Recursion Pharmaceuticals has reached an agreement with the FDA on the design of its registrational Phase 3 clinical trial for REC-4881, an investigational oral MEK1/2 inhibitor for treating familial adenomatous polyposis (FAP).
J.P. Morgan analyst Priyanka Grover has maintained a "Buy" rating on Recursion Pharmaceuticals, setting a price target of $7.
Bank of America Merrill Lynch has issued a neutral rating on Recursion Pharmaceuticals with a price target of $6.00.
Recursion Publishing has signed Dr. Renata Moon for the upcoming release of her book, 'White Coats, Red Flags'.